C. Larsen, G. Pialoux, D. Salmon, D. Antona, L. Strat et al., Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, Eurosurveillance, vol.13, pp.4-6, 2004.

. Mcgovern, The epidemiology, natural history and prevention of hepatitis B : implications of HOV co-infection, Antivir Ther, vol.12, pp.3-13, 2007.

B. Rehermann and M. Nascimbeni, Immunology of hepatitis B virus and hepatitis C virus infection, Nature Reviews Immunology, vol.24, issue.3, pp.215-244, 2005.
DOI : 10.1172/JCI200318509

B. Phung, Hepatitis B and human immunodeficiency virus co-infection, World Journal of Gastroenterology, vol.20, issue.46, p.17360, 2014.
DOI : 10.3748/wjg.v20.i46.17360

D. Konopnicki, A. Mocroft, D. Wit, S. Antunes, F. Ledergerber et al., Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort, AIDS, vol.19, issue.6, pp.593-601, 2005.
DOI : 10.1097/01.aids.0000163936.99401.fe

J. Colin, D. Cazals-hatem, M. Loriot, M. Martinot-peignoux, B. Pham et al., Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, vol.84, issue.4, pp.1306-1316, 1999.
DOI : 10.1002/hep.510290447

C. Thio, E. Seaberg, R. Skolasky, J. Phair, B. Visscher et al., HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) The Lancet, pp.1921-1927, 2002.

L. Piroth, S. Pol, P. Miailhes, K. Lacombe, A. Lopes et al., Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study, Liver International, vol.56, issue.9, 2015.
DOI : 10.1111/liv.12777

E. Rosenthal, C. Roussillon, D. Salmon-céron, A. Georget, S. Hénard et al., Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalit?? 2010 survey, France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS), pp.230-239, 1995.
DOI : 10.1111/hiv.12204

H. World and . Organization, Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Virus Infection. World Health Organization, 2015.

P. Morlat, C. National, and . Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Ministère des Affaires sociales et de la santé. Prise en charge médicale des personnes vivant avec le VIH : rapport 2013: recommandations du groupe d'experts. La documentation française, 2013.

J. Dienstag, Hepatitis B Virus Infection, New England Journal of Medicine, vol.359, issue.14, pp.1486-500, 2008.
DOI : 10.1056/NEJMra0801644

G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman et al., Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses, Gastroenterology, vol.139, issue.4, pp.1218-1247, 2010.
DOI : 10.1053/j.gastro.2010.06.042

P. Marcellin, E. Heathcote, M. Buti, E. Gane, R. De-man et al., Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, vol.359, issue.23, pp.2442-55, 2008.
DOI : 10.1056/NEJMoa0802878

E. Heathcote, P. Marcellin, M. Buti, E. Gane, D. Man et al., Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B, Gastroenterology, vol.140, issue.1, pp.132-175, 2011.
DOI : 10.1053/j.gastro.2010.10.011

P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert et al., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, The Lancet, vol.381, issue.9865, pp.468-75, 2013.
DOI : 10.1016/S0140-6736(12)61425-1

H. Price, D. Dunn, D. Pillay, F. Bani-sadr, T. De-vries-sluijs et al., Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis, PLoS ONE, vol.15, issue.7, p.68152, 2013.
DOI : 10.1371/journal.pone.0068152.s002

J. Molina, P. Cahn, B. Grinsztejn, A. Lazzarin, A. Mills et al., Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial, The Lancet, vol.378, issue.9787, pp.238-284, 2011.
DOI : 10.1016/S0140-6736(11)60936-7

J. Sheldon, N. Camino, B. Rodés, A. Bartholomeusz, M. Kuiper et al., Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir, Antivir Ther, vol.10, issue.6, p.727, 2005.

G. Matthews, E. Seaberg, A. Avihingsanon, S. Bowden, G. Dore et al., Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus, Clinical Infectious Diseases, vol.56, issue.9, pp.87-94, 2013.
DOI : 10.1093/cid/cit002

P. Yéni, A. Nationale-de-recherches-sur-le-sida, H. Les, and . Virales, Direction Générale de la Santé, Ministère de la Santé et des solidarités Prise en charge médicale des personnes infectées par le VIH : rapport 2006 : recommandations du groupe d'experts. Flammarion médecine-sciences, 2006.

P. Yéni, C. National, and . Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Ministère de la santé et des sports Prise en charge médicale des personnes infectées par le VIH : rapport 2010 : recommandations du groupe d'experts. La Documentation Française, 2010.

P. Sax, D. Wohl, M. Yin, F. Post, E. Dejesus et al., Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, The Lancet, vol.385, issue.9987, 2015.
DOI : 10.1016/S0140-6736(15)60616-X

E. Murakami, T. Wang, Y. Park, J. Hao, E. Lepist et al., Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy, Antimicrobial Agents and Chemotherapy, vol.59, issue.6, pp.3563-3572, 2015.
DOI : 10.1128/AAC.00128-15

K. Agarwal, S. Fung, T. Nguyen, W. Cheng, E. Sicard et al., Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection, Journal of Hepatology, vol.62, issue.3, pp.533-573, 2015.
DOI : 10.1016/j.jhep.2014.10.035

H. Izzedine, V. Thibault, M. Valantin, G. Peytavin, L. Schneider et al., Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?, AIDS, vol.24, issue.7, pp.1078-1087, 2010.
DOI : 10.1097/QAD.0b013e3283313f54

. Kdigo-work and . Group, KDIGO Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease, Kidney Int Suppl, vol.31, 2012.

A. Rosenberg, S. Naicker, C. Winkler, and J. Kopp, HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment, Nature Reviews Nephrology, vol.460, issue.3, pp.150-60, 2015.
DOI : 10.1038/nrneph.2015.9

P. Morlat, A. Vivot, M. Vandenhende, F. Dauchy, J. Asselineau et al., Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004???2012, PLoS ONE, vol.22, issue.6, p.66223, 2004.
DOI : 10.1371/journal.pone.0066223.t003

URL : https://hal.archives-ouvertes.fr/hal-01101114

E. Déti, R. Thiébaut, F. Bonnet, S. Lawson-ayayi, M. Dupon et al., Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France, HIV Medicine, vol.11, issue.5, pp.308-325, 2010.
DOI : 10.1111/j.1468-1293.2009.00780.x

. Agence-de-la-de-biomédecine, La maladie rénale chronique Disponible sur http

J. Tourret, I. Tostivint, S. Montcel, J. Bragg-gresham, S. Karie et al., Outcome and Prognosis Factors in HIV-Infected Hemodialysis Patients, Clinical Journal of the American Society of Nephrology, vol.1, issue.6, pp.1241-1248, 2006.
DOI : 10.2215/CJN.02211205

L. Ryom, A. Mocroft, O. Kirk, M. Ross, P. Reiss et al., Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons, AIDS, vol.28, issue.2, pp.187-99, 2014.
DOI : 10.1097/QAD.0000000000000042

G. Lucas, M. Ross, P. Stock, M. Shlipak, C. Wyatt et al., Executive Summary: Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.59, issue.9, pp.1203-1210, 2014.
DOI : 10.1093/cid/ciu730

. Kdigo-work and . Group, KDIGO Clinical Practice Guideline for Glomerulonephritis -Chapter 9: Infection-related glomerulonephritis, Kidney Int Suppl, vol.2, issue.2, pp.200-208, 2012.

F. Lescure, C. Flateau, J. Pacanowski, I. Brocheriou, E. Rondeau et al., HIV-associated kidney glomerular diseases: changes with time and HAART, Nephrology Dialysis Transplantation, vol.27, issue.6, pp.2349-55, 2012.
DOI : 10.1093/ndt/gfr676

URL : https://hal.archives-ouvertes.fr/inserm-00919151

M. Zaidan, F. Lescure, I. Brocheriou, S. Dettwiler, J. Guiard-schmid et al., Tubulointerstitial Nephropathies in HIV-Infected Patients over the Past 15 Years: A Clinico-Pathological Study, Clinical Journal of the American Society of Nephrology, vol.8, issue.6, pp.930-938, 2013.
DOI : 10.2215/CJN.10051012

URL : https://hal.archives-ouvertes.fr/inserm-00919109

B. Stengel, S. Billon, V. Dijck, P. Jager, K. Dekker et al., Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999, Nephrology Dialysis Transplantation, vol.18, issue.9, pp.1824-1857, 1990.
DOI : 10.1093/ndt/gfg233

A. Schoffelen, C. Smit, S. Van-lelyveld, L. Vogt, M. Bauer et al., Diminished Impact of Ethnicity as a Risk Factor for Chronic Kidney Disease in the Current HIV Treatment Era, Journal of Infectious Diseases, vol.212, issue.2, pp.264-74, 2015.
DOI : 10.1093/infdis/jiv026

C. Krawczyk, S. Holmberg, A. Moorman, L. Gardner, G. Mcgwin et al., Factors associated with chronic renal failure in HIV-infected ambulatory patients, AIDS, vol.18, issue.16, pp.2171-2179, 2004.
DOI : 10.1097/00002030-200411050-00009

A. Mocroft, J. Lundgren, M. Ross, M. Law, P. Reiss et al., Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study, PLOS Medicine, vol.15, issue.3, p.1001809, 2015.
DOI : 10.1371/journal.pmed.1001809.s001

S. Amet, J. Bronowicki, D. Thabut, F. Zoulim, M. Bourliere et al., Prevalence of renal abnormalities in chronic HBV infection: The HARPE study, Liver International, vol.32, issue.Suppl. 1, pp.148-55, 2015.
DOI : 10.1111/liv.12480

Y. Chen, Y. Su, C. Li, and S. Hung, 13-year nationwide cohort study of chronic kidney disease risk among treatment-na??ve patients with chronic hepatitis B in Taiwan, BMC Nephrology, vol.147, issue.A8, 2015.
DOI : 10.1053/j.gastro.2014.03.048

C. Pipili, G. Papatheodoridis, and E. Cholongitas, Treatment of hepatitis B in patients with chronic kidney disease, Kidney International, vol.84, issue.5, pp.880-885, 2013.
DOI : 10.1038/ki.2013.249

S. Mauss, F. Berger, N. Filmann, D. Hueppe, J. Henke et al., Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B, Journal of Hepatology, vol.55, issue.6, pp.1235-1275, 2011.
DOI : 10.1016/j.jhep.2011.03.030

S. Koklu, M. Gulsen, Y. Tuna, H. Koklu, O. Yuksel et al., Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B, Alimentary Pharmacology & Therapeutics, vol.29, issue.9, pp.310-319, 2015.
DOI : 10.1111/apt.13036

A. Mocroft, J. Neuhaus, L. Peters, L. Ryom, M. Bickel et al., Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults, PLoS ONE, vol.17, issue.4, p.40245, 2012.
DOI : 10.1371/journal.pone.0040245.t003

A. Mweemba, A. Zanolini, L. Mulenga, D. Emge, B. Chi et al., Chronic Hepatitis B Virus Coinfection Is Associated With Renal Impairment Among Zambian HIV-Infected Adults, Clinical Infectious Diseases, vol.59, issue.12, pp.1757-60, 2014.
DOI : 10.1093/cid/ciu734

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311179

P. Pradat, L. Pogam, M. Okon, J. Trolliet, P. Miailhes et al., Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate, Journal of Viral Hepatitis, vol.24, issue.7, pp.650-657, 2013.
DOI : 10.1111/jvh.12088

J. Tourret, G. Deray, and C. Isnard-bagnis, Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?, Journal of the American Society of Nephrology, vol.24, issue.10, pp.1519-1546, 2013.
DOI : 10.1681/ASN.2012080857

B. Fernandez-fernandez, A. Montoya-ferrer, A. Sanz, M. Sanchez-niño, M. Izquierdo et al., Tenofovir Nephrotoxicity: 2011 Update, AIDS Research and Treatment, vol.26, issue.5, pp.1-11, 2011.
DOI : 10.1128/AAC.00068-10

URL : http://doi.org/10.1155/2011/354908

L. Herlitz, S. Mohan, M. Stokes, J. Radhakrishnan, D. Agati et al., Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities, Kidney International, vol.78, issue.11, pp.1171-1178, 2010.
DOI : 10.1038/ki.2010.318

C. Morén, M. Bañó, I. González-casacuberta, M. Catalán-garcia, M. Guitart-mampel et al., modelling of differential HIV-1 progression and antiretroviral toxicity, Journal of Antimicrobial Chemotherapy, vol.70, issue.8, pp.2330-2336, 2015.
DOI : 10.1093/jac/dkv101

S. Rodriguez-novoa, P. Labarga, D. Avolio, A. Barreiro, P. Albalate et al., Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations, AIDS, vol.24, issue.7, pp.1064-1070, 2010.
DOI : 10.1097/QAD.0b013e32833202e2

B. Kearney, A. Mathias, A. Mittan, J. Sayre, R. Ebrahimi et al., Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.43, issue.3, pp.278-83, 2006.
DOI : 10.1097/01.qai.0000243103.03265.2b

I. Poizot-martin, C. Solas, J. Allemand, V. Obry-roguet, V. Pradel et al., Renal Impairment in Patients Receiving a Tenofovir-cART Regimen, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.4, pp.375-80, 2013.
DOI : 10.1097/QAI.0b013e31827ce4ee

H. Izzedine, J. Hulot, E. Villard, C. Goyenvalle, S. Dominguez et al., Gene Haplotypes and Tenofovir???Induced Proximal Tubulopathy, The Journal of Infectious Diseases, vol.194, issue.11, pp.1481-91, 2006.
DOI : 10.1086/508546

URL : http://jid.oxfordjournals.org/cgi/content/short/194/11/1481

J. Kiser, M. Carten, C. Aquilante, P. Anderson, P. Wolfe et al., The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients, Clinical Pharmacology & Therapeutics, vol.42, issue.2, pp.265-72, 2008.
DOI : 10.1038/sj.clpt.6100269

V. Wanga, C. Venuto, G. Morse, E. Acosta, E. Daar et al., Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202, Pharmacogenetics and Genomics, vol.25, issue.9, 2015.
DOI : 10.1097/FPC.0000000000000156

A. Calcagno, D. Gonzalez-de-requena, M. Simiele, D. Avolio, A. Tettoni et al., Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function, Antimicrobial Agents and Chemotherapy, vol.57, issue.4, pp.1840-1843, 2013.
DOI : 10.1128/AAC.02434-12

T. Cihlar, A. Ray, G. Laflamme, J. Vela, L. Tong et al., Molecular assessment for the potential of renal drug interactions between tenofovir and HIV portease inhibitors, Antivir Ther, vol.12, pp.267-72, 2007.

R. Campo, E. Dejesus, U. Bredeek, K. Henry, H. Khanlou et al., SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen, Clinical Infectious Diseases, vol.56, issue.11, pp.1637-1682, 2013.
DOI : 10.1093/cid/cis1203

A. Mocroft, O. Kirk, P. Reiss, D. Wit, S. Sedlacek et al., Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, issue.11, pp.1667-78, 2010.
DOI : 10.1097/QAD.0b013e328339fe53

T. Berg, F. Zoulim, B. Moeller, H. Trinh, P. Marcellin et al., Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients, Journal of Hepatology, vol.60, issue.4, pp.715-737, 2014.
DOI : 10.1016/j.jhep.2013.11.024

R. Gish, M. Clark, S. Kane, R. Shaw, M. Mangahas et al., Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, vol.10, issue.8, pp.941-947, 2012.
DOI : 10.1016/j.cgh.2012.04.008

P. Marcellin, F. Ii, X. Causse, C. Larrey, D. Pageaux et al., 531 Tenofovir DF i i i and i i in Chronic Hepatitis B (CHB) patients with baseline decreased glomerular filtration rate, J Hepatol, vol.56, p.210, 2012.

M. Tsai, C. Chen, P. Tseng, C. Hung, K. Chiu et al., Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience, Clinical Microbiology and Infection, vol.22, issue.1, 2015.
DOI : 10.1016/j.cmi.2015.05.035

L. Tan, Y. Gilleece, S. Mandalia, A. Murungi, D. Grover et al., Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir, Journal of Viral Hepatitis, vol.52, issue.1, pp.471-479, 2009.
DOI : 10.1111/j.1365-2893.2009.01084.x

E. Vidal-petiot and M. Flamant, Mesure et estimation du débit de filtration glomérulaire. Encyclopédie Médico-Chirurgiale, 2014.

H. Autorité-de and L. Santé, Diagnostic de l'Insuffisance rénale chronique. Disponible sur http

A. Choi, R. Scherzer, P. Bacchetti, P. Tien, M. Saag et al., Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons, American Journal of Kidney Diseases, vol.56, issue.5, pp.872-82, 2010.
DOI : 10.1053/j.ajkd.2010.05.019

H. Autorité-de and L. Santé, Maladie Rénale Chronique de l'adulte -Guide du parcours de soin. Disponible sur http

S. Jose, L. Hamzah, L. Campbell, T. Hill, M. Fisher et al., Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure, Journal of Infectious Diseases, vol.210, issue.3, pp.363-73, 2014.
DOI : 10.1093/infdis/jiu107